On November 9, Roivant Sciences Ltd. rose 5.41% in Regular Trading, trading at $40.625 per share, with turnover of $28.1903 million.
The move followed the company’s fiscal Q2 results and recent pipeline updates, which together improved market sentiment.
For the quarter ended September 30, Roivant Sciences Ltd. reported a net loss of $0.27 per diluted share, wider than $0.17 a year earlier but slightly better than the $0.28 loss expected by the analyst tracked by FactSet. Revenue rose to $35.1 million from $1.6 million a year earlier, far above the $4.3 million consensus expectation, while cash, cash equivalents, restricted cash and marketable securities totaled $4.20 billion.
Recent development milestones also added support: brepocitinib achieved primary and key secondary endpoints in two phase 3 non-infectious uveitis trials; mosliciguat met primary and secondary endpoints in a phase 2 PH-ILD study and advanced into phase 3 development; and brepocitinib was approved in August for adult dermatomyositis and launched in the US.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments